Evidence map›Paper›PMID 40685705›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2025

Superselective Adrenal Artery Embolization as a Novel Alternative Treatment for Aldosterone-Producing Adenomas: A Case of Refractory Hypertension With Concomitant Autonomous Cortisol Secretion.

Zhixin Xu, Li Tao, Rui Xiang, Jing Chang, Jiayi Liu, Min Mao

Abstract readCase Reports
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhixin XuDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li TaoDepartment of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rui XiangDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jing ChangDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jiayi LiuDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Min MaoDepartment of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0003-4720-2892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary aldosteronism (PA) is characterized by an overproduction of aldosterone, leading to hypertension and hypokalemia. Although surgery is an effective treatment for unilateral PA, some patients may be unwilling or unable to undergo this invasive procedure. This case report presents a 51-year-old female patient with refractory hypertension, diagnosed with right-sided hypersecretion of aldosterone and concomitant with autonomous cortisol secretion. The patient declined surgery and was treated with spironolactone as an alternative. Despite optimized medication over 3 months, her blood pressure remained poorly controlled, and she continued to experience hypokalemia and muscle weakness. The patient subsequently underwent right-sided superselective adrenal artery embolization (SAAE). The procedure led to significant reductions in aldosterone and cortisol levels, achieving long-term blood pressure control and biochemical remission with minimal doses of antihypertensive drugs and no need for potassium supplementation. Two years of follow-up confirmed sustained clinical and biochemical improvements, along with evidence of ameliorated target organ damage. This case highlights the potential of SAAE as a feasible treatment option for aldosterone-producing adenomas, offering an alternative therapeutic approach beyond current guidelines.

Indexed as

AdenomaAldosteroneEmbolization, TherapeuticHydrocortisoneHyperaldosteronismHypertensionAdrenal GlandsAntihypertensive AgentsFemaleHumansHypokalemiaMiddle AgedSpironolactoneTreatment OutcomeAldosteroneAntihypertensive AgentsHydrocortisoneSpironolactoneautonomous cortisol secretionfollow‐upprimary aldosteronismsecondary hypertensionsuperselective adrenal artery embolization

Identifiers

PMID40685705
PMCPMC12277535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.